New Novel Molecular Findings in MPNs -Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3* -Not meeting WHO criteria for ET, PV, BCR-ABL1+ CML, myelodysplastic syndromes, or other myeloid neoplasms -Presence of JAK2, CALR or MPL mutation or in the absence of these mutations, presence of another clonal marker ** or absence of reactive myelofibrosis ***
• Minor criteria:
-Presence of at least one of the following, confirmed in two consecutive determinations:
• a. Anemia not attributed to a comorbid condition • b. Leukocytosis >11 x 10 9 /L • c. Palpable splenomegaly • d. LDH increased to above upper normal limit of institutional reference range • e. Leukoerythroblastosis
• Diagnosis of overt PMF requires meeting all three major criteria, and at least one minor criterion Summary • Inclusion of CALR plays a very important role in diagnosing ET and PMF • CSF3R mutation is strongly associated with chronic neutrophilic leukemia • It is important to distinguish true ET from prePMF as the prognosis is much more favorable in ET
